EMBL Ventures raises new life sciences fund
This article was originally published in Scrip
EMBL Ventures, the life sciences-focused venture capital arm of the European Molecular Biology Laboratory, has bucked fundraising trends by completing a first close of its second fund EMBL Technology Fund II at €40 million ($55 million). EMBL Ventures' target is to raise more than €50 million.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.